Next Article in Journal
Novel Capsid-Specific Single-Domain Antibodies with Broad Foot-and-Mouth Disease Strain Recognition Reveal Differences in Antigenicity of Virions, Empty Capsids, and Virus-Like Particles
Previous Article in Journal
Global Vaccine Hesitancy Segmentation: A Cross-European Approach
Previous Article in Special Issue
Delivery Routes for COVID-19 Vaccines
Article

Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines

1
Adjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, D02 R590 Dublin, Ireland
2
Department of Medical Biotechnology, College of Applied Medical Sciences, Qassim University, Buraydah 52571, Saudi Arabia
3
Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
4
Centre for Research on Adaptative Nanostructures and Nanodevices & Advanced Materials Bio-Engineering Research Centre, Trinity College Dublin, D02 PN40 Dublin, Ireland
*
Author to whom correspondence should be addressed.
These authors contributed equally.
Academic Editor: Bert Devriendt
Vaccines 2021, 9(6), 619; https://doi.org/10.3390/vaccines9060619
Received: 1 May 2021 / Revised: 27 May 2021 / Accepted: 1 June 2021 / Published: 8 June 2021
(This article belongs to the Special Issue Recent Advances in Mucosal Vaccines)
Oral vaccination has the potential to offer a safer and more efficacious approach for protection against enteric pathogens than injection-based approaches, especially in developing countries. One key advantage is the potential to induce intestinal immune responses in addition to systemic immunity. In general, antigen delivery via the oral route triggers weak immune responses or immunological tolerance. The effectiveness of oral vaccination can be improved by co-administering adjuvants. However, a major challenge is the absence of potent and safe oral adjuvants for clinical application. Here, the Type II NKT cell activator sulfatide is shown for the first time to be an effective oral adjuvant for Vibrio cholerae vaccine antigens in a mouse model. Specifically, administration of sulfatide with the oral cholera vaccine Dukoral® resulted in enhancement of intestinal antigen-specific IgA in addition to Th1 and Th17 immune responses. In summary, sulfatide is a promising adjuvant for inclusion in an oral cholera vaccine and our data further support the potential of adjuvants targeting NKT cells in new vaccine strategies. View Full-Text
Keywords: adjuvant; oral vaccine; NKT cells adjuvant; oral vaccine; NKT cells
Show Figures

Figure 1

MDPI and ACS Style

Albutti, A.; Longet, S.; McEntee, C.P.; Quinn, S.; Liddicoat, A.; Rîmniceanu, C.; Lycke, N.; Lynch, L.; Cardell, S.; Lavelle, E.C. Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines. Vaccines 2021, 9, 619. https://doi.org/10.3390/vaccines9060619

AMA Style

Albutti A, Longet S, McEntee CP, Quinn S, Liddicoat A, Rîmniceanu C, Lycke N, Lynch L, Cardell S, Lavelle EC. Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines. Vaccines. 2021; 9(6):619. https://doi.org/10.3390/vaccines9060619

Chicago/Turabian Style

Albutti, Aqel, Stephanie Longet, Craig P. McEntee, Shauna Quinn, Alex Liddicoat, Cristiana Rîmniceanu, Nils Lycke, Lydia Lynch, Susanna Cardell, and Ed C. Lavelle 2021. "Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines" Vaccines 9, no. 6: 619. https://doi.org/10.3390/vaccines9060619

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop